Amgen has taken a big stride toward gaining regulatory approval for its biosimilar of Humira, AbbVie’s megablockbuster anti-inflammatory. The Big Biotech reports today that its knockoff of Humira–dubbed ABP 501–hit its marks on equivalency for efficacy and safety for treating plaque psoriasis.

…read more

Source: Amgen declares a head-to-head PhIII win for Humira biosimilar


0 No comments